Viewray (VRAY) Given Coverage Optimism Rating of -0.06
Headlines about Viewray (NASDAQ:VRAY) have been trending somewhat negative this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Viewray earned a daily sentiment score of -0.06 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.1538107685476 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Stock’s Volatility Analysis – ViewRay Inc (NASDAQ: VRAY) (stockspen.com)
- Price to Earnings Ratio to Track – ViewRay Inc (NASDAQ: VRAY) (stocksmarketcap.com)
- Viewray (VRAY) Upgraded to “Sell” by BidaskClub (americanbankingnews.com)
- Time To Buy? Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) and ViewRay, Inc. (NasdaqGM:VRAY)’s ROIC Under … (concordiareview.com)
- Hot Stock’s Highlights – ViewRay Inc (NASDAQ: VRAY) (stocksmarketcap.com)
VRAY has been the subject of a number of research analyst reports. BidaskClub raised Viewray from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Cantor Fitzgerald set a $13.00 target price on Viewray and gave the company a “buy” rating in a research note on Monday, January 8th. Mizuho reissued a “buy” rating and issued a $12.00 target price on shares of Viewray in a research note on Tuesday, January 9th. Finally, B. Riley assumed coverage on Viewray in a research report on Thursday, February 8th. They set a “buy” rating and a $13.50 price objective for the company. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $11.58.
Viewray (NASDAQ:VRAY) last posted its quarterly earnings data on Monday, March 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.13). The firm had revenue of $19.90 million during the quarter, compared to the consensus estimate of $21.23 million. The firm’s revenue was up 23.6% compared to the same quarter last year. equities analysts expect that Viewray will post -0.71 EPS for the current year.
In other news, insider James F. Dempsey sold 75,243 shares of the company’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $7.57, for a total transaction of $569,589.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 62.81% of the stock is owned by corporate insiders.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.